Tanzeum now available in U.S. pharmacies

PHILADELPHIA — GSK announced that Tanzeum (albiglutide), a once-weekly, prescription injectable treatment for Type 2 diabetes in adults, is now available in pharmacies throughout the United States.



Tanzeum was approved by the Food and Drug Administration on April 15, 2014 as an adjunct to diet and exercise to improve glycemic control. The drug is not recommended as first-line therapy for patients inadequately controlled on diet and exercise, according to GSK.



"With approximately 21 million adults diagnosed with diabetes in the US1, and up to 95 percent of those patients living with type 2 diabetes, we're excited that for the appropriate patients Tanzeum is now available as a treatment option for healthcare professionals," said Cheryl MacDiarmid, vice president of GSK's general medicine business.